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plained heterogeneity weakens our inference (Table1).
Table 1. Estimate of Risk for Developing VOD
Subgroup
Investigations
Contributing data
OR with 95%
Confidence Interval I2
All trials Ohashi, Ruutu, Essell 92,
and 98, Carerras,
Thompson
0.33 [0.12, 0.90] 67.6%
Clinical trial Ohashi, Ruutu, Essell 98 0.30 [0.03, 2.80] 70.5%
Observational study Thompson, Carerras,
Essell 92
0.36 [0.11, 1.23] 80.4%
Busulfan conditioned
patients
Essell 92, Essell 98,
Ohashi
0.19 [0.06, 0.59] 41%
TBI conditioned patients Ohashi, Ruutu 0.37 [0.03, 4.84] 67%
Seattle criteria Essell 92, Essell 98,
Ruutu, Thompson
0.40 [0.12, 1.37] 76%
modified Seattle criteria Carerras, Ohashi 0.17 [0.04, 0.64] 0%
Allogeneic transplant
recipients
Essell 92, Essell 98,
Ohashi, Ruutu,
Thompson
0.33 [0.11, 0.99] 73.7%
I2 represents the precentage of unexplained heterogeneity.
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A RETROSPECTIVE ANALYSIS OF THE IMPACT OF ERYTHROPOEITIC
GROWTH FACTOR UTILIZATION ON TRANSFUSION REQUIREMENTS IN
PATIENTS WITH AL AMYLOIDOSIS UNDERGOING AUTOLOGOUS SCT
Baribeault, D.M.1, Shah, B.1, Finn, K.T.1, Seldin, D.C.1, Quillen, K.1,
Sanchorawala, V.1 Boston Medical Center, Boston, MA.
Introduction: The beneﬁt of the addition of erythropoietin-
derived growth factors (EPOs) to neutrophil growth factors to
hasten engraftment and decrease transfusion requirements in pa-
tients undergoing hematopoietic stem cell transplantation is un-
certain. We previously reported the equivalence between erythro-
poetin alfa and long-acting darbepoetin alfa in patients with AL
amyloidosis undergoing autologous stem cell transplantation
(ASCT). To further evaluate EPOs in this patient population, we
examined the time to neutrophil engraftment and transfusion re-
quirements in all patients undergoing ASCT for AL amyloidosis
over a 10 year period. Methods: A retrospective review was con-
ducted of all patients undergoing ASCT between July 1994 and
July 2005. Three groups were compared. Group A consisted of
patients treated with darbepoetin alfa at 200 mcg weekly (n  64),
Group B consisted of patients treated with epoetin alfa at either
150 u/kg thrice weekly or 40,000 units weekly (n  151), and
Group C consisted of those patients not treated with EPOs (n 
161). All groups were treated with GCSF to promote neutrophil
engraftment. Primary endpoints evaluated were mean number of
units of PRBCs transfused and time to neutrophil engraftment. A
secondary endpoint was the proportion of patients requiring PRBC
transfusion. Groups were stratiﬁed by intensity of conditioning
regimen as well as for life-threatening bleeding events and re-
analyzed. A nonparametric analysis of variance was conducted
utilizing the Kruskal-Wallis test with plans for a Dunn comparison
of all three groups in the event of a P value  0.05. Results: The
mean number of PRBC units transfused was 3.23, 4.5, and 3.92 for
Groups A, B, and C, respectively; P  .1591. The mean number of
days to engraftment was 9.87, 10.3, and 10.4 for the groups; P 
.0956. When life threatening bleeding events were excluded, there
was still no signiﬁcant difference, P  .12. In the subgroup of
patients receiving the highest dose (200 mg/m2) of melphalan, the
proportion of patients not requiring RBC transfusion was higher in
the group receiving EPOs (38% versus 23%, P  .0512, 2).
Discussion: In this analysis, we were unable to demonstrate a
beneﬁt for EPOs in the entire patient group, which is heteroge-
nous in terms of chemotherapy dosing and bleeding complications.
However, when we examined those patients receiving the highest
dose of chemotherapy, an increase in the percentage of patients not
requiring RBC transfusion support was seen.
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MELPHALAN-INDUCED SEVERE ORAL MUCOSITIS IS PREVENTED BY
ORAL CRYOTHERAPY IN AUTOLOGOUS HEMATOPOIETIC CELL TRANS-
PLANT RECIPIENTS
Rimkus, C.F.1, Waller, P.1, Oliver, D.A.1, Richart, J.M.1,
Pincus, S.M.1 Saint Louis University, St. Louis, MO.
Background: Oral mucositis is an expected complication of high
dose mephalan chemotherapy due to its cytotoxic effects. Severe
mucositis leads to complications of severe pain requiring narcotic
management, difﬁculty or inability to eat and take oral medica-
tions, and prolonged hospital stays. Melphalan has a very short
plasma half-life making it an ideal candidate for cryotherapy inter-
vention.
Objective: Primary objective is to evaluate whether the cryo-
therapy intervention will reduce mucositis in patients receiving
high dose melphalan compared to historical controls. Secondary
objectives included determining the tolerance of the procedure and
comparing the need for intravenous narcotics to historical controls.
Methods:The program assessed a modiﬁed version of cytotherapy
intervention protocols reported previously by two institutions.
Patients and staff were given written and verbal instructions de-
scribing the oral cryotherapy intervention. The procedure in-
cluded holding cold medium (ice, popsicle, cold ﬂuid) in the mouth
beginning 10 minutes before the melphalan infusion and continu-
ing until 1 hour after the infusion was completed. Results: Con-
secutive patients (multiple myeloma 18, NHL 13, other 3) being
conditioned with melphalan were eligible. The cryotherapy inter-
vention was used 04/04&ndash09/05, (n  20). A retrospective
review of previous consecutive transplants provided the melphalan
matched controls (03/02–03/04), n  14. Most (90%) of the
patients were able to complete the entire procedure for oral cryo-
therapy. Two patient (10%) intermittently followed the procedure
because they felt too full from drinking cold ﬂuid. Subsequently,
cold ﬂuid has been eliminated as an option for treatment. Forty-
three percent of historical controls had severe mucositis compared
to none of the patients who received cryotherapy (Table). Addi-
tionally, a dramatic difference in the amount of opiate used was
noted. In the historical control group 47% of patients required IV
PCA (cummulative dose MSO4 937mg and Fentanyl 11,850 mcg)
compared to 10% in the cryotherapy group (cumulative 68 mg
MSO4) (Table 1). Summary: Cryotherapy was well tolerated and
appeared to decrease mucositis in high dose melphalan recipients.
Additionally, there was a decrease in IV pain medication use re-
sulting in less overall morbidity.
Table 1. Mucositis in Melphalan Recipients
Intervention Patients None/Mild Moderate Severe
No cryotherapy 14 6 (43%) 2 (14%) 6 (43%)*
Cryotherapy 20 17 (85%) 3 (15%) 0
*Two intubated for airway protection.
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PHASE III TRIAL OF VALACYCLOVIR FOR THE PREVENTION OF SHIN-
GLES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
Klein, A.K.1, DesJardins, J.1, Koc, Y.2, Miller, K.B.3, Schenkein, D.S.1,
Sprague, K.S.1, Snydman, D.R.1 1. Tufts-New England Medical Cen-
ter, Boston, MA; 2. Hacettepe University, Ankara, Turkey; 3. Beth
Israel Deaconess Medical Center, Boston, MA.
Despite advances in antiviral therapy, reactivation of latent vari-
cella-zoster virus (VZV) infections remains a signiﬁcant cause of
morbidity following stem cell transplantation (SCT). Twenty-ﬁve
percent or more of patients undergoing SCT will reactivate VZV
in the form of zoster (shingles) within the ﬁrst year after transplant.
Short course (6–12 months) prophylactic therapy with acyclovir
has been shown effective, but compliance with administration up to
5 times daily has been problematic, and outbreaks resumed follow-
ing completion. We undertook a phase III, randomized, double-
blind, placebo-controlled trial of valacyclovir (VACV, 1000 mg
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